GLP-1 receptor agonists like semaglutide are often described as “game changers” for weight loss and cardiovascular health, and in many ways, the data support that claim. Clinical trials suggest meaningful reductions in major cardiovascular events, offering hope for individuals struggling with metabolic disease.
But there’s an important nuance that deserves more attention: what happens when these medications are stopped?
In this conversation, Dr. Bret Scher explores emerging real-world data showing that the benefits of GLP-1s, particularly for cardiovascular risk, appear to depend on continued use. For many individuals, stopping the medication leads to a reversal of progress, raising important questions about long-term strategy, sustainability, and what true metabolic healing looks like.
Are we managing symptoms, or addressing root causes?\
What role should medications play in long-term care?\
How can we use powerful tools like GLP-1s to *support*, rather than replace, sustainable metabolic change?
For some individuals, long-term use may be appropriate and beneficial. But we need to broaden the conversation toward approaches that aim to improve underlying metabolic health, support lasting behavior change, and ultimately reduce reliance on lifelong interventions when possible.
If you’re exploring GLP-1s or are currently taking one, consider speaking with your healthcare provider about how to pair your treatment with sustainable lifestyle strategies such as nutrition, physical activity, and metabolic support, to help maintain progress over time.
GLP-1 medications such as semaglutide have cardiovascular benefit while they are being taken and affect weight loss and heart care.
Large clinical trials show a 15% to 20% relative reduction in major cardiovascular events over five years, or about a 1.5% to 2% absolute reduction.
Those numbers make the drugs look like a broad answer to the metabolic health crisis.
The key question is what happens after people stop taking them.
What happens after discontinuation
In the real world, many people stop, with roughly one-half to two-thirds off the drugs within a year.
A BMJ Medicine study in a VA cohort of more than 300,000 patients examined outcomes after discontinuation.
Continuous GLP-1 use was associated with about an 18% lower risk of heart attack, stroke, or death than sulfonylurea use.
Use for 18 months or less had no clear cardiac benefit.
Benefits started receding within six months of stopping and were essentially gone within 18 months.
Cardiovascular protection depended on ongoing use.
Why the benefit fades
The medication manages the problem without removing its deeper drivers.
GLP-1s can lower weight and temporarily improve metabolic health.
They do not by themselves rebuild eating patterns, physical fitness, metabolic flexibility, or other long-term drivers of cardiometabolic disease.
When lifestyle and metabolic drivers stay the same, risk returns when the medication is removed.
Because the study population was drawn from the VA, cost pressure on adherence was muted, and discontinuation could be even more common where copays are higher.
How the medication fits into care
Lifelong use may make sense for some high-risk patients, but lifelong dependence for millions is not the goal.
GLP-1s are a powerful short-term tool that reduces hunger, quiets food noise, triggers weight loss, and creates room for change.
That window should be used to build durable nutrition habits, higher protein intake, lower refined carbohydrate intake, physical activity, and muscle preservation.
Relying on the drug alone leads to weight regain, worsening metabolic markers, and loss of cardiovascular benefit when use stops.
The aim is durable cardiovascular, metabolic, and mental health rather than a temporary reduction in risk.
Stewardship and implementation
Proper stewardship matters because these medications are becoming more common, not less.
Individuals and clinicians are responsible for using them in ways that pair medication benefit with long-term metabolic recovery.
The Coalition for Metabolic Health recently formed a GLP-1 task force and has a paper on GLP-1 medications and metabolic health.
References
[01:13] Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation — https://doi.org/10.1136/bmjmed-2025-002150